Semaglutide is a weight management research compound currently in stock directly from a verified Chinese manufacturer. Every batch is HPLC-verified and shipped with a Certificate of Analysis (COA). Sourcing is direct — no intermediaries. Minimum order value is $600 USD. International shipping available.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist consisting of 31 amino acids. The molecule is structurally derived from native human GLP-1 with two key modifications: a substitution at position 8 (Aib replaces Ala) that confers resistance to DPP-IV cleavage, and a C18 fatty diacid chain attached via a linker at position 26 that enables albumin binding. These modifications extend the plasma half-life to approximately 7 days, making semaglutide the longest-acting GLP-1 analogue in research use. Its pharmacokinetic profile distinguishes it from older analogues such as liraglutide (t½ ~13h) and exenatide (t½ ~2.4h).
Current preclinical and clinical research on semaglutide spans several areas. In obesity and metabolic research, semaglutide has been studied in rodent models of diet-induced obesity and in large-scale human trials (STEP program), demonstrating dose-dependent reductions in body weight mediated through GLP-1 receptor-driven appetite suppression and delayed gastric emptying. Cardiovascular outcome research (SUSTAIN-6, FLOW) has documented effects on major adverse cardiovascular events and renal endpoints, expanding the research scope beyond glycaemic control. Emerging pre-clinical work explores CNS-level mechanisms including reward circuitry modulation relevant to addictive behaviour models.
PeptidesFromChina.co supplies research-grade semaglutide as lyophilized powder in sealed vials. Purity is verified at ≥98% by HPLC and confirmed by mass spectrometry. Each batch is supported by a Certificate of Analysis. Minimum order quantities are available on request. This compound is supplied strictly for laboratory research use; it is not approved for human administration.
| Chemical Class | GLP-1 Receptor Agonist |
|---|---|
| CAS Number | 910463-68-2 |
| Molecular Formula | C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molecular Weight | 4113.58 Da |
| Sequence Length | 31 amino acids |
| Half-life (research) | ~168 h (7 days) |
| Receptor Target | GLP-1R (GLP-1 receptor) |
| Synonyms | NN9535, semaglutide |
| Storage | -20°C lyophilized; 4°C reconstituted (up to 28 days) |
| Name | Strength | Pack Size | Purity | Availability | Price (USD) |
|---|---|---|---|---|---|
| Semaglutide | 5 mg | 10 vials | ≥98% | In Stock | $40.00 |
| Semaglutide | 10 mg | 10 vials | ≥98% | In Stock | $63.00 |
| Semaglutide | 15 mg | 10 vials | ≥98% | In Stock | $75.00 |
| Semaglutide | 20 mg | 10 vials | ≥98% | In Stock | $88.00 |
| Semaglutide | 30 mg | 10 vials | ≥98% | In Stock | $111.00 |
Testing method: HPLC / LC-MS (["HPLC","LC-MS","Endotoxins","Heavy Metals","Sterility","Water Content","Assay","Visible Particulates"]). Every batch is tested before shipment. Purity ≥99% confirmed per batch.
Certificate of Analysis: Manufacturer COA · Simple COA. Documentation is available for every batch sold.
Semaglutide has been investigated in rodent models of high-fat diet-induced obesity and in clinical trials. Preclinical work demonstrates that GLP-1 receptor activation in the hypothalamus and brainstem reduces food intake via effects on POMC/AgRP neurons and the nucleus tractus solitarius. Human STEP trials documented mean body weight reductions of 14–17% at doses of 2.4 mg/week, establishing semaglutide as a benchmark compound for obesity pharmacology research.
As a GLP-1 receptor agonist, semaglutide potentiates glucose-dependent insulin secretion from pancreatic beta-cells while suppressing glucagon from alpha-cells. Preclinical models of T2D (db/db, HFD/STZ mice) show improved beta-cell function and glycaemic parameters. The glucose-dependent mechanism means insulin secretion is amplified only in the presence of elevated glucose — a feature studied in insulinoma cell line models and isolated islet preparations.
The SUSTAIN-6 and SELECT trials identified significant reductions in major adverse cardiovascular events (MACE) and cardiovascular mortality in subjects with established cardiovascular disease. The FLOW trial extended these observations to renal endpoints including composite kidney disease progression. Preclinical work in atherosclerosis models (ApoE⁻/⁻ mice) suggests GLP-1R-mediated anti-inflammatory effects on vascular macrophages as a potential mechanism. This area remains a high-priority research focus given the overlap of metabolic and cardiovascular disease.
GLP-1 receptors are expressed in reward circuits including the ventral tegmental area (VTA) and nucleus accumbens. Preclinical rodent studies report that semaglutide and other GLP-1R agonists attenuate operant responding for alcohol, nicotine, and high-fat food. This has stimulated research into potential neurobiological mechanisms of compulsive consumption and executive function. Several investigator-initiated studies have translated these findings into early-phase human trials for alcohol use disorder.
Research-grade semaglutide supplied as lyophilized powder is the same amino acid sequence as pharmaceutical products, but is manufactured in peptide synthesis facilities rather than pharmaceutical GMP plants. It lacks excipients (phosphate buffer, propylene glycol, phenol) present in injectable pen formulations. It is intended for laboratory reconstitution and in vitro or in vivo research use — not for clinical or human administration.
Lyophilized semaglutide should be stored at -20°C and protected from light and moisture. Once reconstituted in sterile bacteriostatic water or PBS, solutions are typically stable for 28 days at 2–8°C. Avoid repeated freeze-thaw cycles of reconstituted solution, as peptide aggregation may occur.
Purity is confirmed by reverse-phase HPLC (RP-HPLC) with UV detection at 214 nm, which separates the parent peptide from deletion sequences and synthesis byproducts. Identity is confirmed by electrospray ionisation mass spectrometry (ESI-MS) matching the theoretical monoisotopic mass. Certificates of Analysis are provided with each batch.
PeptidesFromChina.co operates on a B2B wholesale model. Minimum order quantities, pricing tiers, and volume discounts are provided upon request after account verification. Contact us through the request form or the Contact page for a formal quote.
For laboratory research use only. Not for human or veterinary use. PeptidesFromChina.co is a B2B wholesale supplier operating under strict research-use-only terms. All products are sold exclusively for in vitro and preclinical research purposes.